vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this populationCadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment
A company started testing a new diabetes medicine on patients. Watch to see if early results look promising for future testing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.